Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in HIV-infected adults on ART
NCT02475655Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started May 2016; status: completed.
02
Drugs
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02475655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02475655.